In this episode of The Healthcare Theory, we’re joined by Iain MacLeod, co-founder of Aldatu Biosciences, to explore their groundbreaking work in diagnostics for HIV, viral hemorrhagic fevers, and emerging diseases.
Aldatu addresses the global challenge of affordable and accessible drug-resistance testing, focusing on resource-limited settings. Iain shares insights on the innovative Panda technology, which enables rapid and accurate detection of resistant strains even in the most variable viruses. We discuss the journey of developing diagnostics like COVID-19 tests, the role of public benefit corporations in social impact, and navigating global healthcare markets. Don’t miss this in-depth discussion on transforming healthcare through innovation in diagnostics.
Timestamps:
00:00 – Podcast and guest introduction
00:37 – Iain’s background in virology and early work in HIV research
02:16 – The problem: addressing gaps in HIV drug resistance diagnostics
05:34 – The origins of Panda technology for drug resistance testing
07:52 – Challenges in resource-limited healthcare settings
10:19 – Becoming a public benefit corporation and the social impact of diagnostics
14:56 – Pivoting during COVID-19 and Aldatu’s first profit-generating venture
19:32 – How Panda revolutionizes real-time PCR for variable viruses
27:34 – Competing with large diagnostics companies and maintaining affordability
30:54 – Expanding diagnostics into new markets and diseases
36:46 – Future trends: decentralizing diagnostics and iterating on Panda technology